

Innovative drugs: Mapping the pricing, reimbursement and HTA landscape

<https://marketpublishers.com/r/I5652C95666EN.html>

Date: September 2017

Pages: 0

Price: US\$ 695.00 (Single User License)

ID: I5652C95666EN

Abstracts

Widespread patient access to innovative new products is being frustrated in non-US markets by Health Technology Assessments (HTA). Between January 2016 and June 2017, 58 innovative medicines were approved and launched in the US - but what of their status elsewhere? For example, only 35 of the 58 have been approved in the EU and of these many are tied up in HTA reviews. The commercial impact cannot be underestimated: with no predictable outcome, companies cannot plan effectively or understand the competitive environment in which they will operate. Which companies are being impacted? What products have made the grade? When – and where – will new competitive threats emerge?

Delivering a detailed report and usable data set, this ground breaking analysis exposes the pricing, reimbursement and HTA review status of innovative drugs in Australia, Canada, France, Germany and the UK for a clear picture of the competitive landscape.

DISCOVER ON THIS PAGE

Why this report is important to you

Key facts about this report and data

This report will enable you

The deliverables: market analysis and data set

Table of contents

WHY THIS REPORT IS IMPORTANT TO YOU

Pharma prides itself on being an innovative industry. It spends US\$ billions on R&D and negotiates the regulatory regimes to get its products approved. But overcoming the HTA hurdle is neither a standardised nor predictable process with commercially-acceptable pricing and reimbursement decisions far from guaranteed.

The burden of HTA assessment grows heavier as each national - or even sub-national - authority sets its own standards for evidence. Smaller companies and biotechs may not have either the finance or resources to engage. Knowing which companies are currently engaged and the impact on the products is critical competitive intelligence.

KEY FACTS ABOUT THIS REPORT AND DATA

Products: 58 innovative products covered, including ixekizumab (Eli Lilly), nusinersen (Biogen), palbociclib (Pfizer), selexipag (Actelion) and sofosbuvir/velpatasir (Gilead)

Therapy areas: The 58 products cover 13 therapy areas – mainly oncology and neurology but also respiratory, anti-infectives, musculoskeletal and gastrointestinal

Indications: Conditions indicated for the 58 products include cancer (various), dry eye, muscular dystrophy, hepatitis C, IBS, Parkinson's disease and diabetes

Companies: The products of 47 companies are covered including Actelion, Bristol-Myers Squibb, Eli Lilly, Genentech and Gilead

Markets: Detailed information is provided for HTA status in Australia, Canada, France, Germany and the UK

THIS REPORT WILL ENABLE YOU TO

Review the pricing, reimbursement and HTA status of each product at the national level

Profile the therapy areas that are being targeted by innovative drugs

Estimate likely HTA decisions using average timeframes

Identify products that have been approved but not referred for HTA assessment

Assess the impact of HTA systems on smaller companies and biotechs in the innovative drug space

Profile the emerging innovative therapies in key therapy areas

Delivering market analysis and data

This report delivers two competitive analysis resources!

1. Analysis report

Rich in charts and tables, this detailed analytical report provides:

At a glance overview of the approved drugs, therapy areas, routes of administration, company and latest sales performance

Pricing, reimbursement and HTA policies and practices in Canada, France, Germany and the UK

Product-level analysis providing overviews of regulatory approvals, HTA status/market launch and sales (including first half 2017 sales where available)

1. Data Set

Delivered in Microsoft Excel™, all the data used to drive this report can be used for further analysis or to incorporate into competitive intelligence systems. For each product the data covers:

Generic name, brand name, developer company, condition targeted and therapy area

US FDA/EMA/Health Canada approval dates and days to approve

HTA referral, review, decision dates and outcomes where known

Sales performance, where relevant, in local currency and US\$

Summary Contents

Overview

Approved drugs

By therapy area

By Route of Administration

By company

Sales Data

Latest Sales Revenues by Therapy Area (\$m)

P&R/HTA Activity

Canada

France

Germany

UK

Drug status reports

For each of the products covered

Product overview

Regulatory approvals

HTA and market launch

Sales

Products covered

Abaloparatide

Alectinib

Atezolizumab

Avelumab

Betrixaban

Bezlotoxumab

Brigatinib

Brivaracetam

Brodalumab

Cerliponase Alfa

Crisaborole

Daclizumab

Daratumumab

Defibrotide

Deflazacort

Delafloxacin

Dupilumab

Durvalumab

Edaravone

Elbasvir/Grazoprevir

Elotuzumab

Eluxadoline

Enasidenib

Etelcalcetide

Eteplirsen

Glecaprevir/Pibrentasvir

Guselkumab

Ixazomib

Ixekizumab

Lenvatinib

Lifitegrast Ophthalmic Solution

Lixisenatide

Midostaurin

Naldemedine

Necitumumab

Neratinib Maleate

Niraparib

Nusinersen

Obeticholic Acid

Ocrelizumab

Olaratumab

Osimertinib

Palbociclib

Pimavanserin

Plecanatide

Reslizumab

Ribociclib

Rolapitant

Rucaparib

Safinamide

Sarilumab

Selexipag

Sofosbuvir/Velpatasvir

Sofosbuvir/Velpatasvir/Voxilaprevir

Telotristat Ethyl

Valbenazine

Venetoclax

ABOUT FIRSTWORD

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Contents

1. EXECUTIVE SUMMARY

2. RESEARCH METHODOLOGY AND OBJECTIVES

3. OVERVIEW

3.1 Approved drugs

3.2 Sales Data

3.3 P&R/HTA Activity

4. DRUG STATUS REPORTS

4.1 Abaloparatide

4.2 Alectinib

4.3 Atezolizuma

4.4 Avelumab

4.5 Betrixaban

4.6 Bezlotoxumab

4.7 Brigatinib

4.8 Brivaracetam

4.9 Brodalumab

4.10 Cerliponase Alfa

4.11 Crisaborole

4.12 Daclizumab

4.13 Daratumumab

4.14 Defibrotide

4.15 Deflazacort

4.16 Delafloxacin

4.17 Dupilumab

4.18 Durvalumab

4.19 Edaravone

4.20 Elbasvir/Grazoprevir

4.21 Elotuzumab

4.22 Eluxadoline

4.23 Enasidenib

4.24 Eteplirsen

4.25 Eteplirsen

- 4.26 Glecaprevir/Pibrentasvir
- 4.27 Guselkumab
- 4.28 Ixazomib
- 4.29 Ixekizumab
- 4.30 Lenvatinib
- 4.31 Lifitegrast Ophthalmic Solution
- 4.32 Lixisenatide
- 4.33 Midostaurin
- 4.34 Naldemedine
- 4.35 Necitumumab
- 4.36 Neratinib Maleate
- 4.37 Niraparib
- 4.38 Nusinersen
- 4.39 Obeticholic Acid
- 4.40 Ocrelizumab
- 4.41 Olaratumab
- 4.42 Osimertinib
- 4.43 Palbociclib
- 4.44 Pimavanserin
- 4.45 Plecanatide
- 4.46 Reslizumab
- 4.47 Ribociclib
- 4.48 Rolapitant
- 4.49 Rucaparib
- 4.50 Safinamide
- 4.51 Sarilumab
- 4.52 Selexipag
- 4.53 Sofosbuvir/Velpatasvir
- 4.54 Sofosbuvir/Velpatasvir/Voxilaprevir
- 4.55 Telotristat Ethyl
- 4.56 Valbenazine
- 4.57 Venetoclax

5. ACRONYMS USED IN THIS REPORT

I would like to order

Product name: Innovative drugs: Mapping the pricing, reimbursement and HTA landscape

Product link: <https://marketpublishers.com/r/I5652C95666EN.html>

Price: US\$ 695.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I5652C95666EN.html>